Orion Oyj (HEL: ORNAV)

Market Cap	6.73B
Revenue (ttm)	1.26B
Net Income (ttm)	232.30M
Shares Out	n/a
EPS (ttm)	1.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Oct 15, 2024

Volume	5,984
Open	47.25
Previous Close	47.35
Day's Range	47.25 - 47.75
52-Week Range	32.50 - 47.75
Beta	0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2024

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s diseas...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 3,632
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNAV

Financial Performance

In 2023, Orion Oyj's revenue was 1.19 billion, a decrease of -11.26% compared to the previous year's 1.34 billion. Earnings were 216.80 million, a decrease of -37.97%.